Table 3 Univariate and multivariate analysis for progression-free survival in lung adenocarcinoma patients treated with EGFR-TKIs
Variable | Univariate analyses | Multivariate analyses | ||
|---|---|---|---|---|
HR (95% CI) | p | HR (95% CI) | p | |
Gender (male vs. female) | 1.212 (0.795-1.848) | 0.372 | 1.110 (0.626-1.967) | 0.721 |
Age (>60 vs≤60) | 0.833 (0.544-1.274) | 0.399 | 0.811 (0.502-1.310) | 0.392 |
Smoking status (Yes vs. No) | 1.194 (0.740-1.926) | 0.468 | 1.469 (0.760-2.838) | 0.253 |
ECOG PS status (2 or 3 vs. 0 or 1) | 1.623 (0.980-2.687) | 0.060 | 1.183 (0.681-2.056) | 0.552 |
Mutation(Others vs. Exon 19 deletion or L858R) | 3.168 (1.343-7.471) | 0.008 | 2.804 (1.038-7.574) | 0.042 |
Bone metastasis (Yes vs. No) | 0.890 (0.542-1.461) | 0.644 | 0.855 (0.492-1.488) | 0.581 |
Liver metastasis (Yes vs. No) | 1.472 (0.642-3.378) | 0.362 | 1.336 (0.548-3.255) | 0.524 |
Chemotherapy (Yes vs. No) | 0.509 (0.308-0.843) | 0.009 | 0.542 (0.315-0.934) | 0.027 |
Therapy Line (Second vs. First) | 0.671 (0.405-1.113) | 0.123 | 0.533 (0.297-0.956) | 0.035 |
ALP (U/L) (>124 vs≤124) | 1.214 (1.076-1.370) | 0.002 | 1.665 (0.970-2.860) | 0.064 |
DB (μmol/L) (>3.3 vs≤3.3) | 0.567 (0.360-0.895) | 0.015 | 0.569 (0.334-0.968) | 0.038 |
TBA (μmol/L) (>4.0 vs≤4.0) | 1.824 (1.170-2.843) | 0.008 | 1.769 (1.059-2.954) | 0.029 |
HDL (mmol/L) (>1.3 vs≤1.3) | 0.578 (0.368-0.907) | 0.017 | 0.876 (0.522-1.469) | 0.615 |